Balancing Between Concentration and Volume when Developing Patient-Centric Biologics

Christian Jones is the Chief Commercial Officer at Nanoform, a publicly listed NASDAQ company. As part of the management team, he leads all global commercial activities including sales, marketing, business development, partnering and licensing. He works with pharmaceutical and biotech companies to enable improved drug performance by creating high drug load patient-centric medicines through Nanoform's proprietary API nanoparticles and novel formulation technologies. With over two decades of experience spanning the pharmaceutical value chain—from drug discovery to commercial manufacturing—Christian brings a strategic, results-driven approach to accelerating drug development for patients' benefit.He has held senior commercial roles in organizations including Johnson Matthey, Dr Reddy's Laboratories, Prosonix, Tripos Discovery Research, consistently delivering growth across Drug Substance and Drug Product development and manufacturing services. Christian is a chemist by training, holding a Master of Chemistry degree from the University of Leeds, and is a Fellow of the Royal Society of Chemistry. He possesses a deep technical foundation in crystallization science, particle engineering, and respiratory drug delivery, and is passionate about leveraging cutting-edge technologies to advance healthcare innovation.A proven leader with a global perspective, Christian is recognized for his ability to identify and unlock commercial potential, guiding organizations to strategically capitalize on their strengths in an increasingly complex and competitive industry landscape.His ultimate ambition is to touch the lives of a billion patients through the application of Nanoform's technologies. With a wide range of partnerships already established across US, Europe and Japan the company now works with 12 of the top 20 pharma companies globally and are on track to reaching this important milestone!

E is a passionate leader in building device development capabilities and improving combination product development processes. He has 20+ years’ experience in delivery device technology assessment, combination product development, manufacturing process development, commercial scale-up and life cycle management. E currently holds the position of Head of Injection Systems at Takeda. Previously he was Director of device development with AstraZeneca. He built a very strong device team and managed multiple combination product programs in the therapeutic areas of respiratory, inflammation, autoimmune, cardiovascular, renal, and metabolic diseases. Prior to AstraZeneca, he was device lead with Janssen Pharmaceuticals and Becton Dickinson, where he led and launched/relaunched injection device and combination products. E obtained his Bachelor and PhD degrees in mechanical engineering and a master’s degree in polymer physics.

After receiving a B.S. in Chemical Engineering from Clarkson University Dr Lindsey Crawford completed a PhD from Cornell University in the school of Chemical and Biomolecular Engineering. Dr Crawford’s PhD thesis work was under Dr. David Putnam where she focused on targeted drug delivery to the blood brain barrier using P-glycoprotein as a target. She then joined the lab of Dr. Shelly Sakiyama-Elbert as a postdoctoral researcher at Washington University in St. Louis working on biomaterials for regenerative medicine prior to becoming a Senior Scientist at Pfizer. Since joining Pfizer Dr Crawford has been involved in drug product development of multiple modalities used to treat a variety of therapeutic indications. She has worked in development stages pre-clinical through commercial and now has a role where she facilitates strategic conversations between key stakeholders during the drug product development stages to ensure the best possible product is reaching our patients. Dr Crawford also has a passion for career development, and as a group leader aims to foster growth in those around her through the day to day work we do.

Dany Doucet is Director of the Early Engagement and Deviceability group in GSK’s Packaging, Device and Design Solution department. He leads a team of engineers and scientists supporting deviceability efforts to improve probability of technical success of development programs through early evaluation and design of suitable molecules, formulations, primary packaging and devices for complex drug device combination products. He has over 20 years of experience working across all stages of the product and process development lifecycle, from the discovery interface through concept design and selection, registrational submission and commercial supply.

Nicholas (Nick) Schill, PhD is an experienced pharmaceutical and combination product development professional with a passion for developing and implementing innovative solutions. Nick started his industry career with Baxter Healthcare supporting exploratory and early phase R&D programs, bioanalytical development, biologics process development, and a Phase 3 cell therapy clinical development program. At Baxalta, and later with Shire, Nick led or supported numerous combination product development and device development programs for Baxalta/Shire's hematology and immunology franchises. After departing Shire, Nick led the Product Development & Commercialization team at Kymanox, a life sciences consulting firm which provides program strategy and technical leadership for the development of drug-device combination products and medical devices, including injection, infusion, reconstitution, nasal delivery, and electromechanical devices. In April 2025, Nick joined AbbVie to lead the Landscaping and Product Definition team which identifies and evaluates novel and established delivery system technologies of interest from potential third-party partners to support AbbVie’s development pipeline. Nick holds a BS from St. Norbert College and a PhD in Cellular and Molecular Biology from the University of Wisconsin at Madison.